Noxipak

Drug overview for NOXIPAK (fluocinolone acetonide/urea/silicone, adhesive):

Generic name: FLUOCINOLONE ACETONIDE/UREA/SILICONE, ADHESIVE (FLOO-oh-SIN-oh-lone uh-SEET-oh-nide)
Drug class: Topical Corticosteroids
Therapeutic class: Dermatological

Fluocinolone acetonide and fluocinonide are synthetic fluorinated Urea, at concentrations of 10-30%, promotes hydration of keratin and mild corticosteroids. keratolysis in dry and hyperkeratotic skin.

Fluocinolone acetonide and fluocinonide share the actions of the other Urea is used topically in the treatment of dry skin. At concentrations of 10-30%, urea promotes hydration of keratin and mild keratolysis in dry and topical corticosteroids and are used for the relief of the inflammatory hyperkeratotic skin. The drug increases the uptake of water by the stratum manifestations of corticosteroid-responsive dermatoses.

corneum, giving it a high water-binding capacity. Topically applied urea may also have an antipruritic effect. At high concentrations (e.g., 40%), urea is a protein denaturant.

DRUG IMAGES

No Image Available

The following indications for NOXIPAK (fluocinolone acetonide/urea/silicone, adhesive) have been approved by the FDA:

Indications:
None.

Professional Synonyms:
None.

The following dosing information is available for NOXIPAK (fluocinolone acetonide/urea/silicone, adhesive):

Dosing
Administration
Dosing Information
Generic

Fluocinolone acetonide shampoo should be prepared by a pharmacist at the Urea is applied topically as a cream or lotion. The moisturizing effect of time of dispensing the shampoo; contents of the 12-mg capsule should be urea may be enhanced by applying the preparation to the skin while it is mixed with the shampoo base supplied by the manufacturer. The still moist after washing or bathing.

Urea is applied topically to the affected area 1-3 times daily or as directed by a physician. extemporaneously prepared shampoo is stable for 3 months from the time of

compounding. The extemporaneously prepared shampoo must be shaken well prior to administration.

Topical fluocinolone acetonide or fluocinonide cream, gel, ointment, and solution are applied sparingly in thin films and rubbed gently into the skin 2-4 times daily depending on the severity of the condition. Occlusive dressings may be used for severe or resistant dermatoses.

For the treatment of atopic dermatitis in adults, fluocinolone acetonide 0.01% topical oil is applied as a thin film 3 times daily.

For the treatment of moderate to severe atopic dermatitis in children 2 years of age or older, a thin film of fluocinolone acetonide 0.01% topical oil may be applied twice daily to affected areas for no longer than 4 weeks. The topical oil should not be applied to the face or diaper area.

Application to intertriginous areas also should be avoided because of an increased risk of developing potentially irreversible adverse local effects (e.g., striae, atrophy, telangiectasia).

For the treatment of seborrheic dermatitis of the scalp in adults, no more than 30 mL of fluocinolone acetonide 0.01% shampoo is applied to the scalp once daily, lathered, and allowed to remain on the scalp for about 5 minutes. The hair and scalp are then rinsed thoroughly with water.

Fluocinolone acetonide shampoo should not be used with occlusive dressings and patients should be warned that treated areas of the scalp should not be bandaged or otherwise covered or wrapped as to be occlusive, unless directed by a clinician.

For the treatment of psoriasis of the scalp in adults, a thin film of fluocinolone acetonide 0.01% topical oil should be applied to wet or dampened hair and scalp, massaged well, and covered with the manufacturer-supplied shower cap. The oil should be allowed to remain on the scalp overnight or for a minimum of 4 hours following application before being washed off with regular shampoo and rinsed thoroughly with water.

No enhanced Administration information available for this drug.

No dosing information available.

No generic dosing information available.

Moderate List
Hypothalamic-pituitary insufficiency
No disease contraindications

The following adverse reaction information is available for NOXIPAK (fluocinolone acetonide/urea/silicone, adhesive):

Overview
Severe
Less Severe

Adverse reaction overview.

No enhanced Common Adverse Effects information available for this drug.

There are 15 severe adverse reactions.

More Frequent	Less Frequent
None.	Folliculitis Purpura Skin and skin structure infection Skin atrophy

Rare/Very Rare
Adrenocortical insufficiency Bullous dermatitis Cataracts Central serous chorioretinopathy Glaucoma Hypothalamic-pituitary insufficiency Ocular hypertension Skin hypopigmentation Skin striae Skin ulcer Urticaria

There are 26 less severe adverse reactions.

More Frequent	Less Frequent
Erythema Pruritus of skin Skin irritation Stinging of skin	Acute pain at drug application site Blurred vision Headache disorder Paresthesia Pruritus of skin Skin rash Telangiectasia Treatment site sequelae

Rare/Very Rare
Acneiform eruption Alopecia Blistering skin Contact dermatitis Dry skin Dyschromia Glycosuria Hirsutism Hypercortisolism Hyperesthesia Hyperglycemia Miliaria Perioral dermatitis Skin irritation

The following precautions are available for NOXIPAK (fluocinolone acetonide/urea/silicone, adhesive):

Pediatric
Pregnant
Lactation
Geriatric

No enhanced Pediatric Use information available for this drug.

Contraindicated

None

Severe Precaution

None

Management or Monitoring Precaution

None

No enhanced Pregnancy information available for this drug.

No enhanced Lactation information available for this drug.

No enhanced Geriatric Use information available for this drug.